Action(s) initiated or orders passed

July 28, 2026 The Manager- Listing BSE Limited P J Towers, Dalal Street, Fort, Mumbai – 400 001 The Manager- Listing National Stock Exchange of India Limited Exchange Plaza, Bandra – Kurla Complex, Bandra (E), Mumbai – 400 051 Dear Sir/Madam, Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has received a demand notice issued by the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging under the Drugs (Prices Control) Order, 2013 (DPCO, 2013). The Company is currently reviewing the demand notice and will take appropriate steps in accordance with applicable law. In this regard, please find the details as required under the SEBI Circular HO/49/14/14(7)2025- CFD-POD2/I/3762/2026 dated January 30, 2026 attached herewith as Annexure – A. Kindly take the above information on record. Thanking You, For AstraZeneca Pharma India Limited Tanya Sanish Company Secretary & Compliance Officer Annexure – A Sl. No. Particulars Details 1. Name of the authority National Pharmaceutical Pricing Authority (NPPA) 2. Nature and details of the Demand Notice issued by the NPPA for action(s) alleged overcharging under the Drugs (Prices Control) Order, 2013 (‘DPCO, 2013’) of Rs. 79,97,457/- inclusive of interest calculated upto August 10, 2026. 3. Date of receipt of direction or July 27, 2026 order, including any ad-interim or interim orders, or any other communication from the authority 4. Details of the NPPA has alleged that AstraZeneca Pharma violation(s)/contravention(s) India Ltd. sold/marketed Betaloc-50 committed or alleged to be (Metoprolol 50 mg tablets) at an MRP higher committed than the ceiling price notified under DPCO, 2013, and has not implemented the revised ceiling price on stocks available in the market from the notifications i.e. Notification S.O. 644(E) dated 02.03.2016 and Notification S.O. 1352(E) dated 02.06.2016 in respect of Betaloc-50 tablets. This has allegedly resulted in overcharging during the period of June to July 2016, for which NPPA has demanded recovery of the overcharged amount along with applicable interest to be paid within 30 days from the date of receipt of the Notice. 5. Impact on financial, operation or Demand of Rs. 79,97,457/- inclusive of interest other activities of the listed calculated upto August 10, 2026. entity, quantifiable in monetary terms to the extent possible